Selected article for: "pandemic situation and rapidly spread"
Author: Triantafyllou, Tania; Olson, Michael T.; Theodorou, Dimitrios; Zografos, Georgios; Singhal, Saurabh
Title: Esophageal cancer: challenges, concerns, and recommendations for management amidst the COVID-19 pandemic
  • Cord-id: arg71du6
  • Document date: 2020_6_22
    • ID: arg71du6
    Snippet: Since December 2019, the outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, raising great concern, particularly in immunosuppressed cancer patients. The pandemic situation remains extremely dynamic, which necessitates proactive management decisions from oncologists and oncologic surgeons in effort to mitigate the risk of both SARS-CoV-2 infection and cancer metastasis. Esophageal cancer, in particular, is one of the deadliest types of malignancy worldwide, reflecting b
    Document: Since December 2019, the outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, raising great concern, particularly in immunosuppressed cancer patients. The pandemic situation remains extremely dynamic, which necessitates proactive management decisions from oncologists and oncologic surgeons in effort to mitigate the risk of both SARS-CoV-2 infection and cancer metastasis. Esophageal cancer, in particular, is one of the deadliest types of malignancy worldwide, reflecting both aggressive biology and a lack of adequate treatment. Several challenges and concerns regarding the management of esophageal cancer have been raised in light of the ongoing viral pandemic. The primary aim of this review is to summarize the salient evidence for recommendations and optimal treatment strategies for patients with esophageal cancer amidst the COVID-19 pandemic.

    Search related documents:
    Co phrase search for related documents
    • acceptable option and lymph node: 1
    • action course and long term short: 1
    • active infection and adequate treatment: 1, 2
    • active infection and adjuvant treatment: 1
    • active infection and long term short: 1, 2, 3
    • active infection and lung ventilation: 1
    • active infection and lymph node: 1, 2, 3, 4
    • active surveillance and adjuvant treatment: 1
    • active surveillance and locally advanced: 1, 2, 3
    • active surveillance and long term short: 1
    • active surveillance and lymph node: 1, 2